Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.

Kolb EA, Houghton PJ, Kurmasheva RT, Mosse YP, Maris JM, Erickson SW, Guo Y, Teicher BA, Smith MA, Gorlick R.

Pediatr Blood Cancer. 2020 Jan 23:e28098. doi: 10.1002/pbc.28098. [Epub ahead of print]

PMID:
31975571
2.

Tatton-Brown-Rahman syndrome: Six individuals with novel features.

Balci TB, Strong A, Kalish JM, Zackai E, Maris JM, Reilly A, Surrey LF, Wertheim GB, Marcadier JL, Graham GE, Carter MT.

Am J Med Genet A. 2020 Jan 21. doi: 10.1002/ajmg.a.61475. [Epub ahead of print]

PMID:
31961069
3.

Pathogen-specific risk factors in acute outbreaks of respiratory disease in calves.

Pardon B, Callens J, Maris J, Allais L, Van Praet W, Deprez P, Ribbens S.

J Dairy Sci. 2020 Jan 15. pii: S0022-0302(20)30037-0. doi: 10.3168/jds.2019-17486. [Epub ahead of print]

PMID:
31954585
4.

When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors.

Yarmarkovich M, Maris JM.

Cancer Cell. 2019 Dec 9;36(6):575-576. doi: 10.1016/j.ccell.2019.11.006.

PMID:
31951557
5.

Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations.

Li YR, Glessner JT, Coe BP, Li J, Mohebnasab M, Chang X, Connolly J, Kao C, Wei Z, Bradfield J, Kim C, Hou C, Khan M, Mentch F, Qiu H, Bakay M, Cardinale C, Lemma M, Abrams D, Bridglall-Jhingoor A, Behr M, Harrison S, Otieno G, Thomas A, Wang F, Chiavacci R, Wu L, Hadley D, Goldmuntz E, Elia J, Maris J, Grundmeier R, Devoto M, Keating B, March M, Pellagrino R, Grant SFA, Sleiman PMA, Li M, Eichler EE, Hakonarson H.

Nat Commun. 2020 Jan 14;11(1):255. doi: 10.1038/s41467-019-13624-1.

6.

Phase I Clinical Trial of the Wee1 inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase 1 Consortium Report (ADVL1312).

Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ.

Clin Cancer Res. 2019 Dec 19. pii: clincanres.3470.2019. doi: 10.1158/1078-0432.CCR-19-3470. [Epub ahead of print]

PMID:
31857431
7.

ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.

Wang L, Tan TK, Durbin AD, Zimmerman MW, Abraham BJ, Tan SH, Ngoc PCT, Weichert-Leahey N, Akahane K, Lawton LN, Rokita JL, Maris JM, Young RA, Look AT, Sanda T.

Nat Commun. 2019 Dec 9;10(1):5622. doi: 10.1038/s41467-019-13515-5.

8.

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.

Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A, VandenHeuvel S, Stuckwisch A, Wang X, Gillies SD, Patel RB, Farrel A, Rokita JL, Maris J, Hank JA, Morris ZS, Rakhmilevich AL, Sondel PM.

J Immunother Cancer. 2019 Dec 6;7(1):344. doi: 10.1186/s40425-019-0823-6.

9.

Using Patchy Particles to Prevent Local Rearrangements in Models of Non-equilibrium Colloidal Gels.

Immink JN, Maris JJE, Schurtenberger P, Stenhammar J.

Langmuir. 2020 Jan 14;36(1):419-425. doi: 10.1021/acs.langmuir.9b02675. Epub 2020 Jan 6.

PMID:
31763852
10.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.

Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM.

Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071.

11.

PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma.

Lee H, Riad A, Martorano P, Mansfield A, Samanta M, Batra V, Mach RH, Maris JM, Pryma DA, Makvandi M.

J Nucl Med. 2019 Nov 1. pii: jnumed.119.233965. doi: 10.2967/jnumed.119.233965. [Epub ahead of print]

PMID:
31676730
12.

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.

Coggins GE, Farrel A, Rathi KS, Hayes CM, Scolaro L, Rokita JL, Maris JM.

Cancer Res. 2019 Dec 15;79(24):6204-6214. doi: 10.1158/0008-5472.CAN-19-1415. Epub 2019 Oct 31.

PMID:
31672841
13.

ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.

Qadeer ZA, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths LM, Zeineldin M, Filipescu D, Jubierre L, Chowdhury A, Deevy O, Chen X, Finkelstein DB, Bahrami A, Stewart E, Federico S, Gallego S, Dekio F, Fowkes M, Meni D, Maris JM, Weiss WA, Roberts SS, Cheung NV, Jin J, Segura MF, Dyer MA, Bernstein E.

Cancer Cell. 2019 Nov 11;36(5):512-527.e9. doi: 10.1016/j.ccell.2019.09.002. Epub 2019 Oct 17.

PMID:
31631027
14.

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.

Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, Maris JM, Sotillo E, Barash Y, Thomas-Tikhonenko A.

Leukemia. 2019 Oct 7. doi: 10.1038/s41375-019-0580-z. [Epub ahead of print] No abstract available.

PMID:
31591467
15.

Immunotherapy for pediatric brain tumors: past and present.

Foster JB, Madsen PJ, Hegde M, Ahmed N, Cole KA, Maris JM, Resnick AC, Storm PB, Waanders AJ.

Neuro Oncol. 2019 Oct 9;21(10):1226-1238. doi: 10.1093/neuonc/noz077.

PMID:
31504801
16.

Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease.

Testori A, Lasorsa VA, Cimmino F, Cantalupo S, Cardinale A, Avitabile M, Limongelli G, Russo MG, Diskin S, Maris J, Devoto M, Keavney B, Cordell HJ, Iolascon A, Capasso M.

Genes (Basel). 2019 Aug 30;10(9). pii: E663. doi: 10.3390/genes10090663.

17.

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L.

JAMA. 2019 Aug 27;322(8):746-755. doi: 10.1001/jama.2019.11642.

PMID:
31454045
18.

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL.

J Clin Oncol. 2019 Dec 1;37(34):3243-3255. doi: 10.1200/JCO.19.00919. Epub 2019 Aug 6.

PMID:
31386611
19.

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.

Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM.

Clin Cancer Res. 2019 Oct 15;25(20):6044-6051. doi: 10.1158/1078-0432.CCR-19-0798. Epub 2019 Jul 29.

PMID:
31358541
20.

Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children's Oncology Group.

Mazul AL, Weinberg CR, Engel SM, Siega-Riz AM, Zou F, Carrier KS, Basta PV, Vaksman Z, Maris JM, Diskin SJ, Maxen C, Naranjo A, Olshan AF.

Cancer Epidemiol. 2019 Aug;61:165-171. doi: 10.1016/j.canep.2019.06.009. Epub 2019 Jul 4.

PMID:
31279991
21.

Clinical utility of custom-designed NGS panel testing in pediatric tumors.

Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, Gallo D, Lin F, Gleason A, Raman P, Aplenc R, Bagatell R, Minturn J, Mosse Y, Santi M, Tasian SK, Waanders AJ, Sarmady M, Maris JM, Hunger SP, Li MM.

Genome Med. 2019 May 28;11(1):32. doi: 10.1186/s13073-019-0644-8.

22.

Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models.

Makvandi M, Lee H, Puentes LN, Reilly SW, Rathi KS, Weng CC, Chan HS, Hou C, Raman P, Martinez D, Xu K, Carlin SD, Greenberg RA, Pawel BR, Mach RH, Maris JM, Pryma DA.

Mol Cancer Ther. 2019 Jul;18(7):1195-1204. doi: 10.1158/1535-7163.MCT-18-0837. Epub 2019 May 9.

PMID:
31072830
23.

Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.

Oldridge DA, Truong B, Russ D, DuBois SG, Vaksman Z, Mosse YP, Diskin SJ, Maris JM, Matthay KK.

J Natl Cancer Inst. 2019 Nov 1;111(11):1192-1201. doi: 10.1093/jnci/djz027.

PMID:
30793172
24.

Reversible Formation of Thermoresponsive Binary Particle Gels with Tunable Structural and Mechanical Properties.

Immink JN, Maris JJE, Crassous JJ, Stenhammar J, Schurtenberger P.

ACS Nano. 2019 Mar 26;13(3):3292-3300. doi: 10.1021/acsnano.8b09139. Epub 2019 Feb 19.

PMID:
30763513
25.

PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level.

Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi KS, Maris JM, Ansari M, Gumy-Pause F.

J Exp Clin Cancer Res. 2019 Feb 12;38(1):69. doi: 10.1186/s13046-019-1066-6.

26.

Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.

Hill-Kayser CE, Tochner Z, Li Y, Kurtz G, Lustig RA, James P, Balamuth N, Womer R, Mattei P, Grupp S, Mosse YP, Maris JM, Bagatell R.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):401-408. doi: 10.1016/j.ijrobp.2019.01.095. Epub 2019 Feb 7.

PMID:
30738983
27.

Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.

Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL.

J Natl Cancer Inst. 2019 Sep 1;111(9):970-982. doi: 10.1093/jnci/djy209.

PMID:
30698726
28.

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL.

Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17.

PMID:
30655315
29.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
30.

The challenge of defining "ultra-high-risk" neuroblastoma.

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS.

Pediatr Blood Cancer. 2019 Apr;66(4):e27556. doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review.

PMID:
30479064
31.

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM.

J Clin Oncol. 2019 Jan 10;37(2):115-124. doi: 10.1200/JCO.18.00419. Epub 2018 Nov 16.

32.

Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor.

Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, Cardinale A, Testori A, Koster J, de Torres C, Devoto M, Maris JM, Iolascon A, Capasso M.

Int J Cancer. 2018 Dec 1;143(11):2828-2837. doi: 10.1002/ijc.31822. Epub 2018 Oct 4.

33.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.

Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. doi: 10.1158/1078-0432.CCR-18-1381. Epub 2018 Aug 9.

34.

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL.

Front Immunol. 2018 Jul 16;9:1641. doi: 10.3389/fimmu.2018.01641. eCollection 2018.

35.

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL.

Front Immunol. 2018 Jun 18;9:1355. doi: 10.3389/fimmu.2018.01355. eCollection 2018. Erratum in: Front Immunol. 2018 Jul 16;9:1641.

36.

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma.

Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Najaraj S, Walton A, Auvil JMG, Gerhard DS, Yuksel A, Catchpoole D, Hewitt SM, Sondel PM, Seeger R, Maris JM, Khan J.

Clin Cancer Res. 2018 Nov 15;24(22):5673-5684. doi: 10.1158/1078-0432.CCR-18-0599. Epub 2018 May 21.

37.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

38.

Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A.

Cancer Discov. 2018 May;8(5):582-599. doi: 10.1158/2159-8290.CD-16-0861. Epub 2018 Mar 6.

39.

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J.

Nature. 2018 Mar 15;555(7696):371-376. doi: 10.1038/nature25795. Epub 2018 Feb 28.

40.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.

Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

41.

A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.

Toor JS, Rao AA, McShan AC, Yarmarkovich M, Nerli S, Yamaguchi K, Madejska AA, Nguyen S, Tripathi S, Maris JM, Salama SR, Haussler D, Sgourakis NG.

Front Immunol. 2018 Jan 30;9:99. doi: 10.3389/fimmu.2018.00099. eCollection 2018.

42.

Rare MYC-amplified Neuroblastoma With Large Cell Histology.

Matsuno R, Gifford AJ, Fang J, Warren M, Lukeis RE, Trahair T, Sugimoto T, Marachelian A, Asgharzadeh S, Maris JM, Ikegaki N, Shimada H.

Pediatr Dev Pathol. 2018 Sep-Oct;21(5):461-466. doi: 10.1177/1093526617749670. Epub 2018 Feb 9.

PMID:
29426276
43.

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL.

Lancet Child Adolesc Health. 2018 Jan;2(1):25-34. doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3.

44.

QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction.

Deveau P, Colmet Daage L, Oldridge D, Bernard V, Bellini A, Chicard M, Clement N, Lapouble E, Combaret V, Boland A, Meyer V, Deleuze JF, Janoueix-Lerosey I, Barillot E, Delattre O, Maris JM, Schleiermacher G, Boeva V.

Bioinformatics. 2018 Jun 1;34(11):1808-1816. doi: 10.1093/bioinformatics/bty016.

45.

Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM.

Sci Data. 2017 Dec 5;4:170183. doi: 10.1038/sdata.2017.183.

46.

Reproductive Disorders and Leptospirosis: A Case Study in a Mixed-Species Farm (Cattle and Swine).

Mori M, Bakinahe R, Vannoorenberghe P, Maris J, de Jong E, Tignon M, Marin M, Desqueper D, Fretin D, Behaeghel I.

Vet Sci. 2017 Dec 1;4(4). pii: E64. doi: 10.3390/vetsci4040064.

47.

Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.

Hungate EA, Applebaum MA, Skol AD, Vaksman Z, Diamond M, McDaniel L, Volchenboum SL, Stranger BE, Maris JM, Diskin SJ, Onel K, Cohn SL.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx093.

48.

Comprehensive Analysis of Hypermutation in Human Cancer.

Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.

Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.

49.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

50.

Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H.

Nat Commun. 2017 Sep 18;8(1):569. doi: 10.1038/s41467-017-00408-8.

Supplemental Content

Support Center